Rua Bioscience Limited — Director's Dealing 2022

Mar 17, 2022

==> picture [99 x 29] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited; and
Name of listed issuer:		Rua Bioscience Limited(Rua)
Date this disclosure made:		17-Mar-22
Date of last disclosure:		7-Dec-21
Director or senior managergiving disclosure
Full name(s):		Manu Caddie
Name of listed issuer:		Rua Bioscience Limited
Name of related body corporate (if applicable):
Position held in listed issuer:		Kaihautu - Head of Innovation and Regulation of Rua
Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class of affectedquoted financialproducts: Ordinaryshares in Rua
Class of affectedquoted financialproducts:		Ordinaryshares in Rua
Nature of the affected relevant interest(s):		Manu is a director and 50% shareholder of New Zealand Nutraceuticals Limited (NZNL). NZNL is a limited partner of Hikurangi Bioactives Limited Partnership (HBLP) with a 40% economic interest in HBLP. HBLP is the registered holder and beneficial owner of 17,554,367 (before the transactions) and 4,000,000 (after the transactions) ordinary shares in Rua.
For that relevant interest-
Number held in class before acquisition or disposal:		7,021,747
Number held in class after acquisition or disposal:		1,600,000
Current registered holder(s):		HBLP
Registered holder(s) once transfers are registered:		NZNL,Hikurangi Enterprises Limited

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

2

Details of transactions requiring disclosure-

Date of transaction:		17/03/2022
Nature of transaction:		Off-market sale
Name of anyotherpartyorparties to the transaction(if known):		Hikurangi Enterprises Limited and NZNL
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value,describe the consideration:		The aggregate consideration is $6,122,507.56. NZNL's economic interest in that consnideration via its 40% economic interest in HBLP is $2,449,003
Number of financialproducts to which the transaction relates:		13,554,367
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		Yes. Note, however, that Manu Caddie does not have control over HBLP's operational decisions as to whether to undertake these trades in Rua's shares.
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:		No. Prior written clearance was not required for HBLP to trade as Manu Caddie does not have control over HBLP's operational decisions as to whether to undertake these trades in Rua's shares.
Date of the prior written clearance (if any):		N/A
Summary of acquisition or disposal of relevant interest (excluding specified derivatives) Class of affectedquoted financialproducts: Ordinaryshares in Rua
Class of affectedquoted financialproducts:		Ordinaryshares in Rua
Nature of the affected relevant interest(s):		Manu is a director and 50% shareholder of NZNL. NZNL is purchasing 5,421,747 ordinary shares in Rua from HBLP.
For that relevant interest-
Number held in class before acquisition or disposal:		0
Number held in class after acquisition or disposal:		5,421,747
Current registered holder(s):		HBLP
Registered holder(s) once transfers are registered:		NZNL

Details of transactions requiring disclosure-

Details of transactions requiring disclosure-
Date of transaction:		17/03/2022
Nature of transaction:		Off-marketpurchase
Name of anyotherpartyorparties to the transaction(if known):		HBLP
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value,describe the consideration:		$2,449,003.11
Number of financialproducts to which the transaction relates:		5,421,747
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		Yes
Whether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closedperiod:		Yes
Date of theprior written clearance(if any):		15/03/2022

Summary of other relevant interests after acquisition or disposal:

Summary of other relevant interests after acquisition or disposal:
Class ofquoted financialproducts:		Ordinaryshares in Rua
Nature of relevant interest:		Registered and beneficial holder
_For that relevant interest,- _
Number held in class:		194,106
Current registered holder(s):		Manu Caddie

For a derivative relevant interest,- Type of derivative: Details of derivative	For a derivative relevant interest,- Type of derivative: Details of derivative
		N/A
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturity date of the derivative (if any):		N/A
Expiry date of the derivative (if any):		N/A
The price's specified terms (if any):		N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlyingfinancialproducts:		N/A
For that derivative relevant interest,-		N/A
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		N/A

Certification

Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:		17-Mar-22
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: